How to Get Praluent (Alirocumab) in Iowa

What Is Praluent and Why Is It Prescribed?

Praluent (alirocumab) is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that degrades LDL receptors in the liver [1]. By blocking PCSK9, alirocumab increases the number of functional LDL receptors available to clear LDL-C from the bloodstream. The FDA approved alirocumab in July 2015 for adults with heterozygous familial hypercholesterolemia (HeFH) or established ASCVD who require additional LDL-C lowering beyond maximally tolerated statin therapy [2].

In the ODYSSEY OUTCOMES trial (N=18,924), alirocumab 75 to 150 mg every two weeks reduced major adverse cardiovascular events (MACE) by 15% relative to placebo (hazard ratio 0.85 to 95% CI 0.78 to 0.93, P<0.001) in patients who had experienced an acute coronary syndrome within the prior one to twelve months [3]. Mean LDL-C fell from 87 mg/dL at baseline to 40 mg/dL at 48 months in the alirocumab arm [3]. Those results formed the clinical foundation for including PCSK9 inhibitors in the 2018 ACC/AHA cholesterol guideline as a class I, level of evidence A recommendation for very-high-risk ASCVD patients whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin plus ezetimibe [4].

The 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies states: "For very-high-risk patients not at LDL-C goal despite maximally tolerated statin and ezetimibe, a PCSK9 inhibitor is recommended before considering other add-on agents" [5]. HeFH affects approximately 1 in 250 people in the United States, meaning an estimated 12,000 to 15,000 Iowans carry the diagnosis based on Iowa's 2024 census-estimated population of roughly 3.2 million [6].

Who Can Prescribe Praluent in Iowa?

Any licensed prescriber operating within their scope of practice under Iowa law may write a Praluent prescription. That includes physicians (MD or DO), nurse practitioners (ARNP), and physician assistants (PA-C) [7]. Iowa ARNPs practicing under a collaborative practice agreement or full-practice-authority designation may prescribe independently [7]. PAs must practice under physician supervision per Iowa Code 148C but retain full prescriptive authority for Schedule II through V controlled substances and legend drugs, including alirocumab [7].

Specialists who most commonly initiate Praluent include cardiologists, lipidologists, and endocrinologists. Primary care providers initiate a meaningful share of PCSK9 inhibitor prescriptions as well. A 2022 analysis published in the Journal of the American College of Cardiology found that only 37% of ASCVD patients eligible for a PCSK9 inhibitor had received one within 12 months of a qualifying cardiac event, underscoring gaps in prescribing rates that telehealth may help address [8].

Telehealth Prescribing of Praluent in Iowa

Iowa permits telehealth prescribing of non-controlled legend drugs, including alirocumab, provided the prescriber establishes a valid patient-provider relationship before or during the encounter [9]. Under Iowa Board of Medicine guidelines, that relationship may be established via synchronous audio-video visit without an in-person examination for most legend drugs [9].

Telehealth works well here. A cardiologist or internist licensed in Iowa reviews your fasting lipid panel, statin history, cardiovascular risk documentation, and confirms a qualifying diagnosis during a video visit. The provider then sends the prescription to a specialty pharmacy, and the injections are shipped to your Iowa address. Most telehealth platforms that offer PCSK9 inhibitor management complete the initial visit within 48 to 72 hours of intake form submission [10].

The prescriber must hold an active Iowa medical license or an Iowa telehealth registration if their primary license is in another state, per Iowa Code 135D.5 [9]. Patients should confirm this licensure before booking. HealthRX connects Iowa patients with board-certified cardiologists and internists licensed in Iowa who are experienced with PCSK9 inhibitor prior authorization workflows.

Step-by-Step: Getting a Praluent Prescription in Iowa

Step 1. Gather your records. Collect a fasting lipid panel drawn within the past 90 days, documentation of at least one statin trial (drug name, dose, duration), any statin intolerance records, and, if relevant, genetic testing or clinical criteria confirming HeFH [4]. The Dutch Lipid Clinic Network score or Simon Broome criteria are accepted in most Iowa PA forms [11].

Step 2. Book a consult. Schedule with an Iowa-licensed provider, in-person or via telehealth. Bring or upload the records above plus your insurance card. The provider will confirm your LDL-C is at or above 70 mg/dL (for ASCVD) or 100 mg/dL (for HeFH) despite maximally tolerated therapy, matching the thresholds in the 2018 ACC/AHA guideline [4].

Step 3. Receive the prescription. If criteria are met, the provider generates a prescription for alirocumab 75 mg/mL every two weeks (initial dose), noting the clinical justification needed for prior authorization.

Step 4. Prior authorization submission. The prescribing provider submits a PA request to your insurer. Required documentation typically includes LDL-C values on maximally tolerated statin, diagnosis code (ICD-10 E78.01 for HeFH or I25.10 for ASCVD), and evidence of statin plus ezetimibe trial [12]. Iowa commercial payers generally respond to PA requests within 3 to 15 business days.

Step 5. Pharmacy dispensing. Specialty pharmacies such as CVS Specialty, Accredo, or Walgreens Specialty dispense Praluent in Iowa. The medication ships cold-packed and must be stored between 36°F and 77°F (2°C and 25°C) [2].

Step 6. Injection training. The auto-injector pen is designed for self-administration. The prescriber or pharmacist reviews injection technique at the first fill. Clinical trials documented injection-site reactions in 7.2% of alirocumab-treated patients vs. 5.1% placebo, generally mild [3].

Labs Required Before and During Praluent Therapy in Iowa

A fasting lipid panel is the core baseline requirement and must show LDL-C at or above the payer's threshold despite documented statin therapy [4]. Most Iowa insurers also require evidence of a liver function test (AST, ALT) and a comprehensive metabolic panel within the prior 90 days, though the FDA label does not mandate routine LFT monitoring given alirocumab's non-hepatic mechanism [2].

For patients with HeFH, genetic confirmation via LDL receptor, ApoB, or PCSK9 mutation testing strengthens the PA submission but is not universally required [11]. The Familial Hypercholesterolemia Foundation recommends cascade genetic screening of first-degree relatives once a proband is identified [6].

During therapy, a repeat fasting lipid panel at 4 to 8 weeks after initiation confirms response. ODYSSEY OUTCOMES showed mean LDL-C reductions of 54.7% from baseline at 4 months [3]. If LDL-C remains above 70 mg/dL on 75 mg every two weeks, the dose may be up-titrated to 150 mg every two weeks at the 4-to-8-week mark [2].

Thyroid function, CBC, and HbA1c are not part of the standard alirocumab monitoring protocol per the FDA label, though individual providers may include them in a broader cardiometabolic workup [2].

Prior Authorization Requirements for Iowa Commercial Payers

Prior authorization is required by nearly all Iowa commercial payers for Praluent, including plans offered through Wellmark Blue Cross Blue Shield of Iowa, United Healthcare, Aetna, and Medica [12]. The exact criteria differ by plan, but a standard PA checklist for alirocumab in Iowa includes the following items.

Documentation of diagnosis: ICD-10 E78.01 (HeFH heterozygous) or I25.10 (chronic ischemic heart disease without angina) or another qualifying ASCVD code [12]. Baseline LDL-C: most plans require LDL-C at or above 70 mg/dL for ASCVD or 100 mg/dL for HeFH, on maximally tolerated statin [4]. Statin trial: at least one moderate-to-high-intensity statin taken for a minimum of 90 days, or documented intolerance with clinical notes [13]. Ezetimibe trial: most Iowa plans require a 90-day trial of ezetimibe 10 mg before approving a PCSK9 inhibitor, consistent with ACC/AHA stepwise recommendations [4]. Prescriber specialty: some plans require the request to originate from or be co-signed by a cardiologist or lipidologist, though this varies [12].

Appeals are available if a PA is denied. The provider submits a letter of medical necessity, including the patient's 10-year ASCVD risk score, LDL-C trajectory, and any statin-intolerance documentation. Iowa law requires insurers to respond to standard PA appeals within 30 days and expedited appeals within 72 hours under Iowa Code 514J [14].

Iowa Medicaid and Praluent Coverage

Iowa Medicaid (Iowa Health and Wellness Plan, managed by Amerigroup Iowa and Iowa Total Care) does not currently list alirocumab on its Preferred Drug List and does not cover Praluent as of mid-2025 [15]. Evolocumab (Repatha) similarly faces significant access barriers under Iowa Medicaid.

Iowa Medicaid enrollees with HeFH or very-high-risk ASCVD may qualify for the Praluent Patient Services program offered directly by Sanofi/Regeneron, which can provide the drug at no cost for patients who meet income eligibility criteria (generally at or below 600% of the federal poverty level) [16]. The enrollment form is available at praluent.com/support and requires proof of Iowa residency, income documentation, and a prescriber attestation.

For commercially insured Iowa patients, the Praluent Savings Card reduces monthly out-of-pocket cost to as low as $0 for eligible patients, with a maximum annual benefit of $4,700 [16]. Patients on Medicare Part D are not eligible for manufacturer copay cards under federal law.

503A Compounding Pharmacies and Alirocumab in Iowa

Iowa-licensed 503A compounding pharmacies are not a viable source for alirocumab. Biologic monoclonal antibodies like alirocumab cannot be compounded under FDA 503A regulations because they are not on the FDA's 503A bulk drug substances list, and compounding a biologic without FDA authorization would violate the Federal Food, Drug, and Cosmetic Act [17]. Any Iowa 503A pharmacy claiming to compound alirocumab should be reported to the Iowa Board of Pharmacy.

Patients should obtain alirocumab exclusively through licensed specialty pharmacies dispensing the FDA-approved Praluent product manufactured by Sanofi/Regeneron [2].

Transferring a Praluent Prescription to Iowa

If you move to Iowa or switch providers, transferring an existing Praluent prescription follows standard Iowa pharmacy law. Iowa Code 155A.33 permits transfer of a non-controlled prescription between pharmacies, provided the original pharmacy releases the remaining refills [18]. The receiving Iowa pharmacy contacts the originating pharmacy to verify fill history and remaining authorized refills.

If your previous prescriber is not licensed in Iowa, a new Iowa-licensed provider must issue a new prescription. The new provider will review your prior authorization history. If you had an approved PA from another state, Iowa insurers typically require a new PA under the Iowa plan's criteria, though your treatment history (LDL-C response data, prior statin records) substantially simplifies the resubmission [12].

Specialty pharmacies with national networks, such as Accredo or CVS Specialty, can often transfer an active Praluent account to an Iowa dispensing site without requiring the patient to restart the entire enrollment process [19].

How Long Does It Take to Receive Praluent in Iowa?

The timeline from initial consult to first injection depends primarily on the prior authorization process. A streamlined path looks like this: telehealth consult on day 1, PA submission on day 2 or 3, PA approval at 5 to 10 business days, specialty pharmacy processing at 2 to 3 business days, cold-pack shipment at 1 to 2 business days. Total: roughly 14 to 21 calendar days for most Iowa patients [10].

Expedited PA requests, available when the clinical situation is urgent (for example, post-ACS with LDL-C above 100 mg/dL), can compress insurer response time to 72 hours under Iowa Code 514J [14]. Using a prescriber office with a dedicated PA coordinator, or a telehealth platform with built-in PA management, cuts the average time by 3 to 5 business days compared with practices without dedicated support staff [10].

Patients who are uninsured or whose PA is denied should apply simultaneously for the Praluent Patient Services program to avoid delays while an appeal proceeds [16].

Monitoring and Follow-Up After Starting Praluent in Iowa

After the first injection, a fasting lipid panel at 4 to 8 weeks confirms LDL-C response [2]. The ACC/AHA 2018 guideline defines adequate response as LDL-C <70 mg/dL for ASCVD patients and <100 mg/dL for primary-prevention HeFH [4]. If LDL-C at the 4-to-8-week check remains above target on 75 mg every two weeks, the dose is increased to 150 mg every two weeks [2].

Lipid panels every 3 to 12 months thereafter are standard practice per ACC/AHA guidance [4]. The prescribing provider, whether in-person or telehealth-based, should review results and adjust the PA renewal documentation accordingly. Most Iowa payers require annual PA renewals for PCSK9 inhibitors [12].

ODYSSEY OUTCOMES followed patients for a median of 2.8 years and found no new safety signals beyond the injection-site reactions and numerically higher (but not statistically significant) rates of neurocognitive events in the alirocumab arm, which resolved after drug discontinuation in the majority of cases [3]. The FDA label does not include a black-box warning [2].

Cost Management for Iowa Patients

Out-of-pocket cost is the single largest barrier to Praluent adherence in Iowa. The list price for Praluent is approximately $5,850 per year per the Sanofi wholesale acquisition cost as of 2024. Four cost-reduction options exist for Iowa patients.

Commercial copay card (Praluent Savings Card): reduces monthly cost to as low as $0 for commercially insured patients, up to $4,700 annually [16]. Patient assistance program (Praluent Patient Services): provides drug at no cost for uninsured or underinsured patients meeting income criteria [16]. Iowa Prescription Drug Program (IPDP): a state-administered discount program for Iowa residents without drug coverage; alirocumab discounts under IPDP vary by pharmacy but typically provide 15 to 30% off list price [20]. Specialty pharmacy 340B pricing: Iowa-based federally qualified health centers (FQHCs) and qualifying hospitals can dispense alirocumab at 340B pricing for eligible patients, sometimes reducing cost by 20 to 50% [21].

A 2023 analysis in JAMA Cardiology found that PCSK9 inhibitor adherence at 12 months was 58% among patients with zero copay vs. 34% among patients with copays above $10 per month, reinforcing the importance of cost-reduction programs for long-term cardiovascular benefit [22].